RE:Licensing Deal to affect the probability of an acquisitionJfbelanger wrote: Hi there, Would like to have your opinion if the projected Licensing Deals would affect the probability of the company to be acquired from a Large Pharma. The idea behind getting those deals in is to get enough money to go over the P3 + recurrent cashflow over royalties. However, Large Pharma prefer to have Universal distributorship agreement, which makes the company less attractive for an acquisition. I am now guessing that Antibe will go over P3 without being acquired and will obtain more and more Licensing Deals. Thanks
I think ...
ATE will continue to look for partners in other geographies.
They will likely leave USA and Europe until the end.
Any company that looks to partner in USA or Europe could still be interested in acquiring the full business (for the other 2 pain drugs, any future drug development and for all the royalties to follow).
It is hard to say how things play out. Many different potential directions.
Also ... what if ATE's drug does well in COVID trials, does that spark more interest ?
Also ... new molecules (new IP) and new meds, do they spark more interest ?
Regardless ... lots of money to make (IMO).